FASB ASC 360-10-35-17 prescribes a two-step impairment test for finite-lived intangible assets: first test recoverability by comparing carrying amount to undiscounted expected future cash flows, then if not recoverable, measure impairment as the excess of carrying amount over fair value. This differs from the impairment test for indefinite-lived intangibles and goodwill, which skip the recoverability test and go directly to fair value comparison. The undiscounted cash flow test serves as a screen to avoid recognizing impairment when temporary market fluctuations reduce fair value below carrying amount but the asset remains economically recoverable. Choice B incorrectly uses discounted cash flows for measurement, Choice C incorrectly applies a revaluation model not permitted under U.S. GAAP, and Choice D incorrectly exempts finite-lived intangibles from impairment testing. The key framework is the two-step approach: recoverability test using undiscounted cash flows, followed by fair value measurement only if the asset fails the recoverability test.

FASB ASC 350-30-35-1 requires finite-lived intangible assets to be amortized over their useful life, which is the period over which the asset is expected to contribute to the entity's cash flows. The useful life (8 years) represents the economic benefit period and takes precedence over the legal life (12 years) when determining the amortization period. The patent should be amortized systematically over 8 years using a method that reflects the pattern of economic benefits, typically straight-line when the pattern is not reliably determinable. Choice A incorrectly uses legal life over economic life, Choice C incorrectly treats all intangibles as indefinite-lived by default, and Choice D references an outdated goodwill amortization concept. The decision rule is that amortization period equals the shorter of legal life or economic useful life, with economic life being the primary consideration for financial reporting purposes.

FASB ASC 805-20-25-10 requires all identifiable intangible assets acquired in a business combination to be recognized at fair value on the acquisition date, regardless of whether they were previously recognized by the acquiree. The brand name meets the identifiability criteria as it is capable of being separated or divided from the entity and provides future economic benefits. The fact that it was internally developed by the acquiree and not previously recognized is irrelevant in purchase accounting, as the business combination provides a new measurement basis at fair value. Choice A incorrectly applies the prohibition on recognizing internally generated intangibles to the acquirer's accounting for acquired assets, Choice C incorrectly uses historical cost and excessive amortization period, and Choice D incorrectly subsumes identifiable intangibles in goodwill based on their useful life. The principle is that business combinations result in fresh-start accounting at fair value for all identifiable assets, eliminating any book-tax differences or unrecognized internally developed intangibles of the acquiree.

FASB ASC 350-30-35-15 through 35-18 requires indefinite-lived intangible assets to be tested for impairment at least annually and more frequently when indicators suggest the asset may be impaired. The impairment test compares the asset's carrying amount to its fair value, with any excess of carrying amount over fair value recognized as an impairment loss in the period identified. Increased competition represents a triggering event requiring an interim impairment test beyond the annual requirement. Choice A incorrectly amortizes an indefinite-lived asset and limits testing to loss periods, Choice C incorrectly requires fair value remeasurement with gain recognition, and Choice D incorrectly exempts indefinite-lived intangibles from impairment testing. The key framework is that indefinite-lived intangibles are not amortized but must be tested for impairment using a fair value test, with more frequent testing when adverse indicators arise.

FASB ASC 350-20-35-30 requires goodwill to be tested for impairment between annual tests if events or circumstances indicate it is more likely than not that goodwill is impaired. A significant adverse legal ruling that reduces expected future cash flows is a clear triggering event requiring an interim impairment test as of the date the event occurred (September 30). The entity cannot wait until the annual test date when impairment indicators arise during the year. Choice A incorrectly defers testing despite the triggering event, Choice C incorrectly suggests amortizing goodwill which is prohibited under current GAAP, and Choice D incorrectly requires automatic full write-off without performing the impairment test. The professional judgment framework requires immediate testing when significant adverse events occur, as delaying recognition of impairment would misstate the financial position and violate the timely recognition principle.

FASB ASC 350-20-35-3C requires goodwill to be tested for impairment at least annually and more frequently if events or circumstances indicate it is more likely than not that goodwill is impaired. The combination of sustained revenue decline, loss of a major customer, and market capitalization falling below book value represents multiple triggering events that indicate it is more likely than not (greater than 50% likelihood) that the fair value of the reporting unit is below its carrying amount. Choice B incorrectly suggests general market volatility alone requires quarterly testing, when entity-specific adverse effects are needed. Choice C incorrectly limits testing to disposal situations, and Choice D incorrectly treats goodwill as having a finite life. The professional judgment framework requires evaluating whether the totality of adverse events and circumstances, both qualitative and quantitative, indicates a more-likely-than-not threshold for impairment has been met.

FASB ASC 350-20-35-2 through 35-13 prescribes the goodwill impairment test, which compares the reporting unit's carrying amount to its fair value. When the carrying amount ($120 million) exceeds fair value ($110 million), an impairment loss is recognized for the difference ($10 million), but limited to the amount of goodwill allocated to that reporting unit ($25 million). The impairment loss reduces goodwill directly and cannot exceed the carrying amount of goodwill. Choice B incorrectly allocates impairment to other assets beyond goodwill, Choice C incorrectly defers recognition until disposal, and Choice D incorrectly writes goodwill to zero when the impairment is only $10 million. The key principle is that goodwill impairment is measured as the excess of carrying amount over fair value, capped at the goodwill balance, ensuring goodwill cannot be written down below zero or create a deferred debit.

FASB ASC 805 requires identifiable intangible assets acquired in a business combination to be recognized separately from goodwill at fair value on the acquisition date. The customer list meets the separability criterion as it is separately transferable, making it an identifiable intangible asset that must be recognized at fair value. However, assembled workforce is specifically excluded from separate recognition under ASC 805-20-55-6 and must be included in goodwill, even though it provides future economic benefits. Choice A incorrectly recognizes assembled workforce separately, which violates the explicit prohibition in ASC 805. Choice C incorrectly includes the customer list in goodwill despite it meeting the identifiability criteria, and Choice D misclassifies the customer list as tangible rather than intangible. The key decision rule is that all identifiable intangible assets meeting the contractual-legal or separability criteria must be recognized separately at fair value, except for assembled workforce which is always subsumed in goodwill.

FASB ASC 350-20-35-30 requires goodwill to be tested for impairment at least annually, regardless of whether triggering events exist, with more frequent testing required only when events and circumstances indicate it is more likely than not that goodwill is impaired. The annual test is mandatory and cannot be skipped even with stable operations. General interest rate increases without entity-specific adverse effects do not constitute a triggering event requiring interim testing, as the standard focuses on entity-specific indicators rather than broad economic changes. Choice A overstates the impact of general interest rates, Choice B incorrectly eliminates the mandatory annual test, and Choice C mischaracterizes what constitutes a triggering event. The decision framework distinguishes between the mandatory annual test (required regardless of indicators) and interim testing (required only with specific adverse indicators affecting the reporting unit's fair value).

FASB ASC 805-20-25-10 and ASC 350-30-35-17A specifically require in-process research and development (IPR&D) acquired in a business combination to be recognized as an identifiable intangible asset at fair value, regardless of whether it has reached technological feasibility. IPR&D is initially classified as indefinite-lived until the project is completed or abandoned, at which point its useful life is reassessed and it either begins amortization (if completed) or is written off (if abandoned). This treatment differs from internally generated R&D, which is expensed as incurred under ASC 730. Choice A incorrectly applies the internal R&D expensing rule to acquired IPR&D, Choice C incorrectly includes it in goodwill despite its identifiability, and Choice D misclassifies it as inventory. The critical distinction is that acquired IPR&D in a business combination receives asset recognition at fair value, while internally generated R&D is expensed, creating an important exception to the general R&D accounting rules.